Literature DB >> 3389302

Prognosis of congestive heart failure and predictors of mortality.

J N Cohn1, T S Rector.   

Abstract

The interaction of physiologic variables that appear to be predictive of prognosis in patients with severe congestive heart failure was examined in a series of 139 patients referred to a heart failure service. Left ventricular ejection fraction, peak oxygen consumption during a progressive maximal exercise test and resting plasma norepinephrine concentration were identified as the strongest univariate predictors of prognosis. Examination of their interaction was accomplished by stratifying each variable into quartiles and then pooling quartiles for bivariate analysis. The data demonstrate that ejection fraction has the most profound effect on survival calculated from maximal oxygen consumption and norepinephrine concentration, but that each of the variables provides additional independent prognostic information when added to survival estimated from any of the other variables. Therefore, ventricular function, exercise tolerance and sympathetic nervous system activation appear to provide independent insight into the prognosis of patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3389302     DOI: 10.1016/s0002-9149(88)80081-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  25 in total

1.  Comparison between segmental wall motion and wall thickening in patients with coronary artery disease using quantitative gated SPECT software.

Authors:  M B Imran; K Morita; I Adachi; M Konno; N Kubo; T Mochizuki; C Katoh; T Kohya; A Kitabatake; E Tsukamoto; N Tamaki
Journal:  Int J Card Imaging       Date:  2000-08

2.  Significance of adaptation mechanisms in adriamycin induced congestive heart failure.

Authors:  P K Singal; N Siveski-Iliskovic; N Kaul; M Sahai
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

Review 3.  Six minute walk test: a simple and useful test to evaluate functional capacity in patients with heart failure.

Authors:  Carlo Rostagno; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2008-02-26       Impact factor: 3.397

Review 4.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 5.  Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.

Authors:  J N Cohn
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  Gated planar technetium 99m-labeled sestamibi myocardial perfusion image inversion for quantitative scintigraphic assessment of left ventricular function.

Authors:  K A Williams; L A Taillon
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

7.  Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.

Authors:  B A van Hout; G Wielink; G J Bonsel; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 8.  The rationale for combined use of diuretics, digitalis, and vasodilators in congestive heart failure.

Authors:  T W Smith; M A Pfeffer
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

9.  Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study.

Authors:  Gregory W Woo; Susan Petersen-Stejskal; James W Johnson; Jamie B Conti; Juan A Aranda; Anne B Curtis
Journal:  J Interv Card Electrophysiol       Date:  2005-03       Impact factor: 1.900

10.  Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure.

Authors:  Wei Jiang; Christopher O'Connor; Susan G Silva; Maragatha Kuchibhatla; Michael S Cuffe; Dwayne D Callwood; Bosh Zakhary; Elizabeth Henke; Rebekka M Arias; Ranga Krishnan
Journal:  Am Heart J       Date:  2008-07-07       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.